SecBot SecBot
PRESS-RELEASE ·Filed Nov 3, 2026

XENE

Xenon Pharmaceuticals Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed13d 9h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor upcoming conference presentations for potential updates on azetukalner clinical trial progress or regulatory milestones. No immediate trading catalyst from this filing.

DirectionNeutral
Confidencehigh
Horizonweeks

azetukalner

◆ Mixed Named in this press release
Impact
Phase
Filed/NDA under FDA review
Time to market
If the FDA accepts the NDA for filing (expected mid-November 2026), a standard 10-month review would set a PDUFA target action date around mid-2027. The drug could potentially launch in the second half of 2027 if approved.
Next catalyst
None dated

What to watchThe next near-term catalyst is the FDA's 60-day filing acceptance decision on the azetukalner NDA, expected around mid-November 2026. If accepted, a PDUFA date (likely standard review, ~10 months, pointing to mid-2027) would be set. The Q3 2026 earnings call on Nov 9 may also provide updates on the psychiatry program pause and the X-TOLE3/X-ACKT epilepsy trials. The psychiatry safety overhang and the stock's 46% decline from its 52-week high mean the FDA filing acceptance and any clarity on the depression program restart timeline are the key swing factors.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$39.19
T+0 close · Nov 3, 2026 · via day close
Latest settled
+7.43%
T+5 · $42.10 · next T+20 in 16d
Vs SPY
+8.34%
α at T+5
Latest observation
+3.83%
T+7 · FF3 residual α
  1. T+0 · Nov 4 $39.19entry
  2. T+1 · 12d ago −3.85%α +0.56% · $37.68
  3. T+5 · 6d ago +7.43%α +8.34% · $42.10
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xenon Pharmaceuticals announced its participation in four upcoming investor conferences in Q4 2026, with no financial results or material business updates disclosed. The press release is a routine corporate communication with no impact on the company's fundamentals.

Key Facts

  • Xenon will present at four investor conferences in Q4 2026: Guggenheim, Stifel, Jefferies, and Evercore.
  • No financial results, guidance, or material business developments were disclosed.
  • The company's lead molecule is azetukalner, a KV7 potassium channel opener in late-stage development for epilepsy and depression.

Financial Impact

No financial data provided in the filing.

Risk Factors

  • No material information disclosed; stock movement unlikely from this filing alone.
  • Clinical-stage biotech risk: azetukalner development outcomes remain uncertain.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3394743

Track record

19 reports on XENE

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
  2. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  4. Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 2/10 Viewing Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
  8. Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
  9. Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
  10. Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 8h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026